Skip to content

EV / sales at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
Stryker logo
StrykerSYK
5.4×-1.3×
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
0.7×-0.2×
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
2.9×-0.7×
Globus Medical logo
Globus MedicalGMED
3.6×-0.2×
Alphatec Holdings logo
Alphatec HoldingsATEC
2.7×-0.3×

Other financials

Income statement

See full
Revenue$20.9M-36.5%
Gross profit$12.0M-40.9%
Operating income-$2.9M-375%
Net income-$3.1M-5,426%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$12.2M+124%
Total debt$15.0M-34.9%
Total equity$48.6M+10.8%
Total assets$78.0M-18.6%

Cash flow

See full
Operating cash flow-$2.1M-265%
CapEx$194.0K-83.7%
Free cash flow-$2.3M-2,753%

Valuation

See full
Market cap$59.05M-32.5%
Enterprise value$61.89M-41.5%
P/E32.3×
P/S0.5×-0.2×

Profitability

See full
Gross margin62.3%+4.2pp
Operating margin4.8%+2.8pp
Net margin1.5%+0.8pp
FCF margin6.4%+4.1pp

Returns & leverage

See full
Return on equity3.9%+2.1pp
Debt / equity0.3×-0.2×
Current ratio3.3×+1.0×

Where this comes from

Calculated from Xtant Medical Holdings’s reported figures.

Based on the most recent quarter.

The official record: Xtant Medical Holdings’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xtant Medical Holdings's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xtant Medical Holdings's EV / sales?
Xtant Medical Holdings (XTNT) reported EV / sales of 0.7× in Q1 2026.
How has Xtant Medical Holdings's EV / sales changed year-over-year?
Xtant Medical Holdings's EV / sales decreased by 2.1% year-over-year, from 0.7× to 0.7×.
What is the long-term trend for Xtant Medical Holdings's EV / sales?
Over 5 years (2020 to 2025), Xtant Medical Holdings's EV / sales has grown at a -18.2% compound annual growth rate (CAGR), from 2.3× to 0.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.